MorphoSys AG Reports Fourth Quarter and Full Year 2022 Finan

Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 Monjuvi U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9

Related Keywords

Germany , United States , United Kingdom , Planegg , Bayern , Massachusetts , Boston , California , Canada , Dennis Riedl , Julia Neugebauer , Eamonn Nolan , Lucinda Crabtree , Charlotte Lohmann , Monjuvi Minjuvi , Thomas Biegi , Jean Paul Kress , Janssen Biotech Inc , Xencor Inc , Linkedin , Twitter , Drug Administration , Constellation Pharmaceuticals Inc , Nasdaq , Novartis , Exchange Commission , Morphosys Group Key Figures , Development Rd Expenses , Share Of Loss Associates , Chief Executive Officer , Constellation Pharmaceuticals , Sung Lee , Chief Financial Officer , Management Board , Events After , Fourth Quarter , Chief Legal Officer , Morphosy Management Board , Net Profit Loss , Full Year , Royalty Pharma , Net Loss , Sys Group Key Figures , Operating Expenses , Impairment Losses , Financial Assets , Equity Method , Tax Benefit , Net Profit , Financial Statements , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Janssen Biotech , Morphosy Annual Report , Investor Relations , Morphosys , Reports , Fourth , Quarter , Bull , Ear , 022 , Financial , Results , Rovides , Corporate , Update ,